Biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday that it will present 17 abstracts at the 19th ECCO Congress, with data from its inflammatory bowel disease (IBD) portfolio. The event, held in Stockholm from 21-24 February 2024, will feature nine oral presentations and eight posters.

Key data presentations includes post-hoc analyses of the SEQUENCE trial comparing risankizumab (SKYRIZI versus ustekinumab for Crohn's disease (CD) outcomes. The COMMAND Phase 3 study showed risankizumab as a maintenance therapy in ulcerative colitis (UC), and U-ENDURE trial results exhibited long-term safety of upadacitinib (RINVOQ) in Crohn's disease (CD).

The research underscores AbbVie's commitment to advancing standards of care in IBD and understanding the gastroenterology community's needs.

Risankizumab is not approved for ulcerative colitis treatment.

SKYRIZI, an interleukin-23 (IL-23) inhibitor, selectively blocks IL-23 by binding to its p19 subunit. Approved by the FDA and EMA, SKYRIZI treats plaque psoriasis, psoriatic arthritis and Crohn's disease.

RINVOQ, a selective JAK inhibitor developed by AbbVie, is being studied in various immune-mediated inflammatory diseases, including Crohn's disease and ulcerative colitis.

With a robust clinical trial program, AbbVie is committed to cutting-edge research in inflammatory bowel diseases. The company aims to eliminate the burden of IBD and make a positive impact on patients' lives. AbbVie's mission is to discover and deliver innovative solutions across key therapeutic areas, including immunology, oncology, neuroscience, and eye care.